Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Other 1Lymphoid 1Gynecologic 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Fitness Trackers × Tumor-Agnostic × Clear all
NCT03971266 2025-09-02

Movement and Fitness Trackers in Determining Performance Status

University of Southern California

Phase NA Terminated
31 enrolled
Tumor-Agnostic

Neoplasms

NCT02779725 2023-11-08

SCH

University of Utah

Phase NA Completed
884 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡